Orthobiologics Market Size to Reach USD 10.2 Billion by 2025: Grand View Research, Inc.

News provided by

Grand View Research, Inc.

07 Feb, 2017, 10:30 GMT

SAN FRANCISCO, February 7, 2017 /PRNewswire/ --

The global orthobiologics market is expected to reach USD 10.2 billion by 2025, according to a new study by Grand View Research, Inc. The orthobiologics market is predominantly driven by the increasing orthopedic disease and musculoskeletal disease burden globally. Moreover, emerging technological innovations in biomaterials, used in the production of orthobiologics are presumed to accelerate the market demand over the forecast period. These predominantly include modifications in graft designs, advent of recombinant biologic agents, stem cell therapy and cultured tissue scaffolds.

     (Logo: http://photos.prnewswire.com/prnh/20150105/723757 )

These advancements are accompanied with the benefits such as enhanced biocompatibility, reduced surgical time and smaller incisions. Furthermore, these novel solutions are presumed to efficiently reduce the recurrence of post-operative complications, which in turn is expected to boost the orthobiologics market during the forecast period.

Browse full research report with TOC on "Orthobiologics Market Analysis By Product (DBM, Allograft, BMP, Viscosupplementation, Synthetic Bone Substitutes, Stem Cell), By Application (Spinal Fusion, Reconstructive Surgery, Trauma Repair), By End Use, And Segment Forecasts, 2014 - 2025" at: http://www.grandviewresearch.com/industry-analysis/orthobiological-products-market

Further Key Findings From the Study Suggest: 

  • In 2015, visco supplementation accounted for the largest share in the product segment owing to being a cost efficient therapeutic alternative for symptomatic management of osteoarthritis
  • Spinal fusion held the largest share in the application segment in 2015, owing to presence of third party insurers and reimbursement structure for fusion enhancement products thus triggering growth
  • In 2015, North America accounted for the dominant share owing to consistent efforts of industry players in promoting awareness pertinent to the orthobiological products resulting in significant rise in adoption rate
  • Asia Pacific is anticipated to exhibit an exponential CAGR as a consequence of significant surge in healthcare spending and awareness levels with respect to the availability of orthobiologics
  • The prominent players are consistently indulging into extensive strategies to gain competitive position including regional expansion and mergers & acquisitions to capture a greater market share
  • For instance, in November 2015, Bioventus acquired BioStructures, a bioabsorbable bone graft developer. This acquisition was carried out to expand orthobiologics product portfolio and grafting solutions in order to expand their market share

Browse related reports by Grand View Research: 

Grand View Research has segmented the orthobiologics market on the basis of product, application, end use, and region: 

  • Orthobiologics Product Outlook (Revenue, USD Billion, 2014 - 2025) 
    • Demineralized Bone Matrix(DBM)
    • Allograft
    • Bone Morphogenetic Protein (BMP)
    • Viscosupplementation
    • Synthetic Bone Substitutes
    • Stem Cell Therapy
  • Orthobiologics Application Outlook (Revenue, USD Billion, 2014 - 2025) 
    • Spinal Fusion
    • Trauma Repair
    • Reconstructive Surgery
  • Orthobiologics End-use Outlook (Revenue, USD Billion, 2014 - 2025) 
    • Hospitals
    • Orthopedic Clinics
  • Orthobiologics Regional Outlook (Revenue, USD Billion, 2014 - 2025) 
    • North America
      • U.S
      • Canada
    • Europe
      • Germany
      • UK
    • Asia Pacific
      • Japan
      • China
      • India
    • Latin America
      • Brazil
      • Mexico
    • Middle East and Africa
      • South Africa

Read Our Blog: Orthobiologics - A cost efficient and therapeutically advanced alternative to mechanical orthopedic solutions

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com

Web: http://www.grandviewresearch.com  

SOURCE Grand View Research, Inc.